0001179110-21-000524.txt : 20210111
0001179110-21-000524.hdr.sgml : 20210111
20210111200942
ACCESSION NUMBER: 0001179110-21-000524
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210105
FILED AS OF DATE: 20210111
DATE AS OF CHANGE: 20210111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MILANO VINCENT
CENTRAL INDEX KEY: 0001187159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31918
FILM NUMBER: 21522132
MAIL ADDRESS:
STREET 1: C/O VIROPHARMA INC
STREET 2: 405 EAGLEVIEW BLVD
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000861838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043072298
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 4843481600
MAIL ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: HYBRIDON INC
DATE OF NAME CHANGE: 19951211
4
1
edgar.xml
FORM 4 -
X0306
4
2021-01-05
0
0000861838
IDERA PHARMACEUTICALS, INC.
IDRA
0001187159
MILANO VINCENT
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BLVD., SUITE 212
EXTON
PA
19341
1
1
0
0
President & CEO
Common Stock
2021-01-05
4
S
0
2740
3.9051
D
211821
D
Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,438 Restricted Stock Units ("RSUs") on January 3, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Of the reported securities beneficially owned, 53,875 shares are represented by unvested RSUs.
/s/ Vincent J. Milano
2021-01-06